Breast cancer genetics: What we know and what we need

Breast cancer results from genetic and environmental factors leading to the accumulation of mutations in essential genes. Genetic predisposition may have a strong, almost singular effect, as with BRCA1 and BRCA2, or may represent the cumulative effects of multiple low-penetrance susceptibility alleles. Here we review high- and low-penetrance breast-cancer-susceptibility alleles and discuss ongoing efforts to identify additional susceptibility genes. Ultimately these discoveries will lead to individualized breast cancer risk assessment and a reduction in breast cancer incidence.

[1]  M. Swift,et al.  Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. , 1986, Journal of the National Cancer Institute.

[2]  M. Swift,et al.  Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.

[3]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[4]  D Morrell,et al.  Incidence of cancer in 161 families affected by ataxia-telangiectasia. , 1991, The New England journal of medicine.

[5]  W. McGuire,et al.  Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. , 1992, Human pathology.

[6]  M. Stratton,et al.  A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome , 1992, Nature Genetics.

[7]  An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. , 1993 .

[8]  D. Easton,et al.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. , 1993, American journal of human genetics.

[9]  J. Bringer,et al.  Androgen receptor gene mutation in male breast cancer. , 1993, Human molecular genetics.

[10]  D. Easton,et al.  The genetic epidemiology of BRCA1 , 1994, The Lancet.

[11]  D. Easton,et al.  The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium. , 1994, Lancet.

[12]  D. Birnbaum,et al.  Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. , 1994, Anticancer research.

[13]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[14]  N. Hynes,et al.  The biology of erbB-2/neu/HER-2 and its role in cancer. , 1994, Biochimica et biophysica acta.

[15]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[16]  J. Foekens,et al.  Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. , 1995, Gene.

[17]  M. Seller,et al.  Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.

[18]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[19]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[20]  J. Struewing,et al.  BRCA1 mutations in young women with breast cancer , 1996, The Lancet.

[21]  C. Croce,et al.  ATM mutations in cancer families. , 1996, Cancer research.

[22]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[23]  M. Stratton,et al.  Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus , 1996, Nature Genetics.

[24]  I. Verma,et al.  Transcriptional activation by BRCA1 , 1996, Nature.

[25]  J. Rommens,et al.  The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds , 1996, Nature Genetics.

[26]  J Isola,et al.  Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.

[27]  F. Couch,et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.

[28]  M. Lai,et al.  A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells. , 1997, Cancer research.

[29]  A. Ashworth,et al.  Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation , 1997, Nature Genetics.

[30]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[31]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[32]  G. Eichele,et al.  Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 , 1997, Nature.

[33]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[34]  K. Isselbacher,et al.  Heterozygous ATM mutations do not contribute to early onset of breast cancer , 1997, Nature Genetics.

[35]  B. Koller,et al.  BRCA1 required for transcription-coupled repair of oxidative DNA damage. , 1998, Science.

[36]  I. Bleiweiss,et al.  Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. , 1998, American journal of human genetics.

[37]  D J Schaid,et al.  Increased Risk for Cancer in Patients with the Peutz-Jeghers Syndrome , 1998, Annals of Internal Medicine.

[38]  B. Ponder,et al.  Thymic lymphomas in mice with a truncating mutation in Brca2. , 1998, Cancer research.

[39]  A. Lindblom,et al.  The role of ataxia-telangiectasia heterozygotes in familial breast cancer. , 1998, Cancer research.

[40]  J. Isola,et al.  Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. , 1998, British Journal of Cancer.

[41]  D. Berry,et al.  Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. , 1998, Journal of the National Cancer Institute.

[42]  L. Holmberg,et al.  Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Hui Tian,et al.  BRCA1 physically associates with p53 and stimulates its transcriptional activity , 1998, Oncogene.

[44]  B. Ponder,et al.  Involvement of Brca2 in DNA repair. , 1998, Molecular cell.

[45]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[46]  A. Vincent-Salomon,et al.  No significant predictive value of c‐ erbB‐2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer , 1998, International journal of cancer.

[47]  A. Aurias,et al.  Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families , 1999, British Journal of Cancer.

[48]  D. Livingston,et al.  BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. , 1999, Cancer research.

[49]  C. Wang,et al.  Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. , 1999, Science.

[50]  H. Inskip,et al.  Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia , 1999, British Journal of Cancer.

[51]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[52]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[53]  C. Mathew,et al.  Identification of germline missense mutations and rare allelic variants in the ATM gene in early‐onset breast cancer , 1999, Genes, chromosomes & cancer.

[54]  W. Foulkes,et al.  Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. , 1999, Journal of the National Cancer Institute.

[55]  S. Elledge,et al.  Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. , 1999, Science.

[56]  L. Kruglyak.  Prospects for whole-genome linkage disequilibrium mapping of common disease genes , 1999, Nature Genetics.

[57]  M B Daly,et al.  Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. , 1999, American journal of human genetics.

[58]  Nazneen,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[59]  P. Lønning,et al.  Screening breast cancer patients for Norwegian ATM mutations , 2000, British Journal of Cancer.

[60]  S. Seal,et al.  BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  Jong-Soo Lee,et al.  hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response , 2000, Nature.

[62]  D. Livingston,et al.  In search of the tumour-suppressor functions of BRCA1 and BRCA2 , 2000, Nature.

[63]  J. Klijn,et al.  ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. , 2000, American journal of human genetics.

[64]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[65]  K. Seibert,et al.  Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. , 2000, Cancer research.

[66]  Anglian Breast Cancer Study Group.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000 .

[67]  R A Irvine,et al.  Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. , 2000, Cancer research.

[68]  E. Gillanders,et al.  Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[70]  M. Stratton,et al.  The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  T. Rebbeck,et al.  Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  J. Peto,et al.  High constant incidence in twins and other relatives of women with breast cancer , 2000, Nature Genetics.

[73]  J. Sudbø,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[74]  K Nasmyth,et al.  Splitting the chromosome: cutting the ties that bind sister chromatids. , 2000, Novartis Foundation symposium.